203925-23-9Relevant articles and documents
Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)- piperidine inhibitors of farnesyl-protein transferase: Design and synthesis of in vivo active antitumor compounds
George Njoroge,Vibulbhan, Bancha,Rane, Dinananth F.,Robert Bishop,Petrin, Joanne,Patton, Robert,Bryant, Mathew S.,Chen,Nomeir, Amin A.,Lin,Liu, Ming,King, Ivan,Chen, Jianping,Lee, Suining,Yaremko, Bohdan,Dell, Janet,Lipari, Philip,Malkowski, Michael,Li, Zujun,Catino, Joseph,Doll, Ronald J.,Girijavallabhan,Ganguly, Ashit K.
, p. 4290 - 4301 (2007/10/03)
Novel tricyclic Ras farnesyl-protein transferase (FPT) inhibitors are described. A comprehensive structure-activity relationship (SAR) study of compounds arising from substitution at the 3-position of the tricyclic pyridine ring system has been explored. In the case of halogens, the chloro, bromo, and lode analogues 19, 22, and 28 were found to be equipotent. However, the fluoro analogue 17 was an order of magnitude less active. Whereas a small alkyl substituent such as a methyl group resulted in a very potent FPT inhibitor (SCH 56580), introduction of bulky substituents such as tert-butyl compound 33, or a phenyl group, compound 29, resulted in inactive FPT inhibitors. Polar groups at the 3-position such as amine 5, alkylamino 6, and hydroxyl 12 were less active. Whereas compound SCH 44342 did not show appreciable in vive antitumor activity, the 3-bromo-substituted pyridyl N- oxide amide analogue 38 was a potent FPT inhibitor that reduced tumor growth by 81% when administered q.i.d. at 50 mpk and 52% at 10 mpk. These compounds are nonpeptidic and do not contain sulfhydryl groups. They selectively inhibit FPT and not geranylgeranyl-protein transferase-1 (GGPT-1). They also inhibit H-Ras processing in COS monkey kidney cells and soft agar growth of Ras-transformed cells.
